z-logo
Premium
Labeling D+ RBCs for flow cytometric quantification of fetomaternal hemorrhage after the RBCs have been coated with anti‐D
Author(s) -
Kumpel Belinda M.
Publication year - 2001
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1046/j.1537-2995.2001.41081059.x
Subject(s) - flow cytometry , antibody , medicine , incubation , andrology , microbiology and biotechnology , staining , fetus , fluorescence , immunology , pathology , chemistry , pregnancy , biology , biochemistry , physics , quantum mechanics , genetics
BACKGROUND: D– patients may receive Rh immunoglobulin (RhIg) before blood samples are taken for estimation of the volume of fetomaternal hemorrhage (FMH) by flow cytometry. Anti‐D bound to the fetal D+ cells may then block the binding of conjugated D MoAb. This may reduce the fluorescence of the D+ cells, which would lead to ambiguity over setting the positions of the markers on histograms and may result in erroneous values of FMH. STUDY DESIGN AND METHODS: Labeling methods were compared by using FITC‐BRAD 3 (anti‐D) and/or FITC‐anti‐IgG (Fab fragment) with mixtures of D+ (R1r) and D– (rr) cells when the D+ cells had first been coated with various amounts (0 molecules/cell and 600‐13,000 molecules/cell) of anti‐D (RhIg). Variables examined were antibody concentrations, the order and times of incubation with the antibodies, and the effect of washing between the uptake of the antibodies used. RESULTS: In all cases, D+ cells were strongly labeled after incubation with 50 μL of FITC‐BRAD‐3 and then after washing with 50 μL of FITC‐anti‐human IgG, with both incubations being for 30 minutes at 37°C. With this double‐staining procedure, the fluorescence of D+ cells was found to be similar regardless of how much anti‐D (RhIg) was previously bound and greater than that with FITC‐BRAD‐3 alone, giving an enhanced signal‐to‐noise ratio. CONCLUSION: As the testing laboratory may not know if the patient has received prophylactic RhIg, this labeling method would be suitable for all samples.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here